bozak

Wyeth and Elan Take Hits on Bad Trials

Biotech bull, if all Bapineuzumab needs to do is "not kill anyone" to get approved for an unmet need, why didn't DNDN's drug get approved? They had a huge unmet need, a great safety profile and better efficacy than Bapineuzumab (primary goal met), yet they didn't get approved.